BR0317326A - Method of reducing cardiovascular disease in an at-risk individual - Google Patents

Method of reducing cardiovascular disease in an at-risk individual

Info

Publication number
BR0317326A
BR0317326A BR0317326-7A BR0317326A BR0317326A BR 0317326 A BR0317326 A BR 0317326A BR 0317326 A BR0317326 A BR 0317326A BR 0317326 A BR0317326 A BR 0317326A
Authority
BR
Brazil
Prior art keywords
cardiovascular disease
risk
reducing
reducing cardiovascular
risk individual
Prior art date
Application number
BR0317326-7A
Other languages
Portuguese (pt)
Inventor
Jefferson J Gregory
Victoria Christian
Robert M Califf
Raymond J Lipicky
Original Assignee
King Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc filed Critical King Pharmaceuticals Inc
Publication of BR0317326A publication Critical patent/BR0317326A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO DE REDUZIR DOENçA CARDIOVASCULAR EM UM INDIVìDUO EM RISCO". A presente invenção refere-se a métodos e formas de dosagem para reduzir e/ou prevenir a incidência de doença cardiovascular, incluindo ataques cardíacos, em indivíduos que estão em risco, como os indivíduos sofrendo de hipertensão. Os tratamentos e formas de dosagem da presente invenção se referem à administração de um diurético, como diurético tiazida como Thalitone <32>, ou sozinho ou em combinação com um inibidor de ACE, como ramipril ou ramiprilat como Altace <32>, para reduzir e/ou evitar a incidência de doença cardiovascular, ou seja, ataques ou deficiência cardíaca, em indivíduos que sofrem de hipertensão ou estão em risco."METHOD OF REDUCING CARDIOVASCULAR DISEASE IN AN INDIVIDUAL AT RISK". The present invention relates to methods and dosage forms for reducing and / or preventing the incidence of cardiovascular disease, including heart attacks, in individuals who are at risk, such as those suffering from hypertension. The treatments and dosage forms of the present invention relate to the administration of a diuretic such as thiazide diuretic such as Thalitone <32>, either alone or in combination with an ACE inhibitor such as ramipril or ramiprilat such as Altace <32> to reduce and / or prevent the incidence of cardiovascular disease, ie heart attacks or disability, in individuals suffering from hypertension or at risk.

BR0317326-7A 2002-12-16 2003-12-16 Method of reducing cardiovascular disease in an at-risk individual BR0317326A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43384502P 2002-12-16 2002-12-16
PCT/US2003/041056 WO2004056360A1 (en) 2002-12-16 2003-12-16 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination

Publications (1)

Publication Number Publication Date
BR0317326A true BR0317326A (en) 2005-11-16

Family

ID=32681973

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317326-7A BR0317326A (en) 2002-12-16 2003-12-16 Method of reducing cardiovascular disease in an at-risk individual

Country Status (10)

Country Link
EP (1) EP1589965A1 (en)
JP (1) JP2006511567A (en)
KR (1) KR20050102080A (en)
CN (1) CN1731996A (en)
AU (1) AU2003303208A1 (en)
BR (1) BR0317326A (en)
CA (1) CA2508269A1 (en)
IL (1) IL169148A0 (en)
MX (1) MXPA05006399A (en)
WO (1) WO2004056360A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667643A4 (en) 2003-08-28 2008-03-05 Nitromed Inc Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20080234353A1 (en) 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
JP2008531579A (en) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド Nitric oxide enhanced diuretic compounds, compositions and methods of use
US9769354B2 (en) 2005-03-24 2017-09-19 Kofax, Inc. Systems and methods of processing scanned data
US9767354B2 (en) 2009-02-10 2017-09-19 Kofax, Inc. Global geographic information retrieval, validation, and normalization
US9576272B2 (en) 2009-02-10 2017-02-21 Kofax, Inc. Systems, methods and computer program products for determining document validity
US10146795B2 (en) 2012-01-12 2018-12-04 Kofax, Inc. Systems and methods for mobile image capture and processing
TWI492166B (en) 2012-01-12 2015-07-11 Kofax Inc Systems and methods for mobile image capture and processing
US9355312B2 (en) 2013-03-13 2016-05-31 Kofax, Inc. Systems and methods for classifying objects in digital images captured using mobile devices
US9208536B2 (en) 2013-09-27 2015-12-08 Kofax, Inc. Systems and methods for three dimensional geometric reconstruction of captured image data
EP2973226A4 (en) 2013-03-13 2016-06-29 Kofax Inc Classifying objects in digital images captured using mobile devices
US20140316841A1 (en) 2013-04-23 2014-10-23 Kofax, Inc. Location-based workflows and services
JP2016518790A (en) 2013-05-03 2016-06-23 コファックス， インコーポレイテッド System and method for detecting and classifying objects in video captured using a mobile device
US9386235B2 (en) 2013-11-15 2016-07-05 Kofax, Inc. Systems and methods for generating composite images of long documents using mobile video data
US9760788B2 (en) 2014-10-30 2017-09-12 Kofax, Inc. Mobile document detection and orientation based on reference object characteristics
US10242285B2 (en) 2015-07-20 2019-03-26 Kofax, Inc. Iterative recognition-guided thresholding and data extraction
US9779296B1 (en) 2016-04-01 2017-10-03 Kofax, Inc. Content-based detection and three dimensional geometric reconstruction of objects in image and video data
US11062176B2 (en) 2017-11-30 2021-07-13 Kofax, Inc. Object detection and image cropping using a multi-detector approach
CN109524075A (en) * 2018-10-22 2019-03-26 平安医疗健康管理股份有限公司 Drug expenditure risk of exceeding criterion control method and device based on data processing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055904A (en) * 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP1589965A1 (en) 2005-11-02
AU2003303208A1 (en) 2004-07-14
WO2004056360A1 (en) 2004-07-08
KR20050102080A (en) 2005-10-25
MXPA05006399A (en) 2006-01-27
JP2006511567A (en) 2006-04-06
CA2508269A1 (en) 2004-07-08
CN1731996A (en) 2006-02-08
IL169148A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
BR0317326A (en) Method of reducing cardiovascular disease in an at-risk individual
BR0211274A (en) Combination of an aldosterone receptor antagonist and an hmg co-reductase inhibitor
WO2005107747A3 (en) Diindolymethane formulations for the treatment of leiomyomas
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
BRPI0517481A (en) method for treating, controlling or preventing a protozoan parasitic disease or disorder, and, pharmaceutical composition
WO2004080482A3 (en) Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
ATE303800T1 (en) RAMIPRIL TO PREVENT CARDIOVASCULAR INCIDENT
NO20056252L (en) Therapeutic and prophylactic methods for neuromuscular disorders
BR0312933A (en) Pharmaceutical composition, pharmaceutical dosage unit, method for treating one or more diseases associated with a vascular condition, and therapeutic combination.
BRPI0519656A2 (en) combination therapy comprising telmisartan and hydrochlorothiazide
NO20054216L (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
WO2005002506A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites
WO2004108080A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants
AR044452A1 (en) COMBINATION OF A P2X7 RECEIVER ANTAGONIST AND AN ALFA TUMOR NECROSIS FACTOR INHIBITOR
Douglas Clinical guidelines for the treatment of hypertension in African Americans
HUP0204089A2 (en) Method and composition for treating resistance to antihypertensives and related conditions
WO2005020919A3 (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor
WO2004110392A3 (en) Compositions and methods for treating coronavirus infection and sars
Vinson et al. Slow infusion for the prevention of akathisia induced by prochlorperazine: a randomized controlled trial
MXPA03006477A (en) Method of treatment of type i diabetes.
Kumar Hypertension and ischemic stroke
DE50312224D1 (en) DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
UY28221A1 (en) PREPARATIONS FOR COMBINATION OF ACETILSALICYL ACID FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES
BR0308517A (en) Combination of an aldosterone receptor antagonist and bile acid sequestering agent
Farsang et al. Where are we with the management of hypertension? From science to clinical practice

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]